From press release on April 5, 2007
“The VentrAssist US BTT trial will involve up to 140 patients at leading heart transplant hospitals in America.
..............................
“The target clinical performance of the VentrAssist in the BTT trial is for 75 percent of the patients to either have a heart transplant or still be listed for heart transplant at 180 days after implant of the VentrAssist.
- Forums
- ASX - By Stock
- VCR
- dt and btt trials running together
VCR
ventracor limited
dt and btt trials running together, page-7
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.